$EKSO
EKSO BIONICS HOLDINGS, INC.

2021 Q1 Form 10-Q Financial Statement

#000154908421000025 Filed on April 29, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $1.910M $1.468M
YoY Change 30.11% -59.4%
Cost Of Revenue $675.0K $831.0K
YoY Change -18.77% -58.8%
Gross Profit $1.235M $637.0K
YoY Change 93.88% -60.16%
Gross Profit Margin 64.66% 43.39%
Selling, General & Admin $3.771M $4.707M
YoY Change -19.89% -8.19%
% of Gross Profit 305.34% 738.93%
Research & Development $603.0K $711.0K
YoY Change -15.19% -48.63%
% of Gross Profit 48.83% 111.62%
Depreciation & Amortization $126.0K $164.0K
YoY Change -23.17% -33.6%
% of Gross Profit 10.2% 25.75%
Operating Expenses $4.374M $5.418M
YoY Change -19.27% -16.79%
Operating Profit -$3.139M -$4.781M
YoY Change -34.34% -2.67%
Interest Expense $26.00K $52.00K
YoY Change -50.0% -57.02%
% of Operating Profit
Other Income/Expense, Net -$531.0K $2.247M
YoY Change -123.63% -237.1%
Pretax Income -$3.670M -$2.530M
YoY Change 45.06% -61.37%
Income Tax
% Of Pretax Income
Net Earnings -$3.670M -$2.534M
YoY Change 44.83% -61.32%
Net Earnings / Revenue -192.15% -172.62%
Basic Earnings Per Share -$0.34
Diluted Earnings Per Share -$0.34 -$436.2K
COMMON SHARES
Basic Shares Outstanding 10.75M shares 87.05M shares
Diluted Shares Outstanding 10.75M shares

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $49.54M $8.520M
YoY Change 481.46% -7.79%
Cash & Equivalents $49.54M $8.516M
Short-Term Investments
Other Short-Term Assets $640.0K $410.0K
YoY Change 56.1% -19.61%
Inventory $2.154M $2.483M
Prepaid Expenses
Receivables $2.276M $2.658M
Other Receivables $0.00 $0.00
Total Short-Term Assets $54.61M $14.06M
YoY Change 288.32% -16.47%
LONG-TERM ASSETS
Property, Plant & Equipment $1.096M $1.530M
YoY Change -28.37% -34.36%
Goodwill $189.0K
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $235.0K $182.0K
YoY Change 29.12% 30.0%
Total Long-Term Assets $1.899M $2.882M
YoY Change -34.11% -28.4%
TOTAL ASSETS
Total Short-Term Assets $54.61M $14.06M
Total Long-Term Assets $1.899M $2.882M
Total Assets $56.50M $16.94M
YoY Change 233.47% -18.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.652M $1.999M
YoY Change -17.36% -19.2%
Accrued Expenses $1.475M $1.716M
YoY Change -14.04% -47.78%
Deferred Revenue $1.493M $1.231M
YoY Change 21.28% 1.65%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $2.170M
YoY Change -100.0% -6.99%
Total Short-Term Liabilities $5.981M $7.550M
YoY Change -20.78% -22.25%
LONG-TERM LIABILITIES
Long-Term Debt $1.990M $0.00
YoY Change -100.0%
Other Long-Term Liabilities $42.00K $45.00K
YoY Change -6.67% -16.67%
Total Long-Term Liabilities $2.032M $45.00K
YoY Change 4415.56% -97.9%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.981M $7.550M
Total Long-Term Liabilities $2.032M $45.00K
Total Liabilities $15.53M $11.72M
YoY Change 32.55% -28.24%
SHAREHOLDERS EQUITY
Retained Earnings -$202.8M -$185.8M
YoY Change 9.13% 4.57%
Common Stock $13.00K $6.000K
YoY Change 116.67% -91.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $40.98M $5.228M
YoY Change
Total Liabilities & Shareholders Equity $56.50M $16.94M
YoY Change 233.47% -18.77%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$3.670M -$2.534M
YoY Change 44.83% -61.32%
Depreciation, Depletion And Amortization $126.0K $164.0K
YoY Change -23.17% -33.6%
Cash From Operating Activities -$2.000M -$1.722M
YoY Change 16.14% -66.74%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $37.30M $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $38.71M -$589.0K
YoY Change -6672.5% -108.7%
NET CHANGE
Cash From Operating Activities -$2.000M -$1.722M
Cash From Investing Activities $0.00
Cash From Financing Activities $38.71M -$589.0K
Net Change In Cash $36.68M -$2.356M
YoY Change -1656.75% -249.02%
FREE CASH FLOW
Cash From Operating Activities -$2.000M -$1.722M
Capital Expenditures $0.00
Free Cash Flow -$1.722M
YoY Change -66.78%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001549084
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.06667
CY2021Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P9M
CY2021Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2021Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-37854
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
Ekso Bionics Holdings, Inc.
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
99-0367049
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1414 Harbour Way South
CY2021Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1201
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Richmond
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94804
CY2021Q1 dei City Area Code
CityAreaCode
510
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
984-1761
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2021Q1 dei Trading Symbol
TradingSymbol
EKSO
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12654994 shares
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49539000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12862000 USD
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
129000 USD
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
42000 USD
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2276000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3224000 USD
CY2021Q1 us-gaap Inventory Net
InventoryNet
2154000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
1978000 USD
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
636000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
356000 USD
CY2021Q1 us-gaap Assets Current
AssetsCurrent
54605000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
18420000 USD
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1096000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1172000 USD
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
568000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
685000 USD
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
235000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
320000 USD
CY2021Q1 us-gaap Assets
Assets
56504000 USD
CY2020Q4 us-gaap Assets
Assets
20597000 USD
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1652000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1501000 USD
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1475000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1429000 USD
CY2021Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1493000 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1496000 USD
CY2021Q1 us-gaap Notes Payable Current
NotesPayableCurrent
814000 USD
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0 USD
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
547000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
548000 USD
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
5981000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4974000 USD
CY2021Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1644000 USD
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1806000 USD
CY2021Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
2262000 USD
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
3075000 USD
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
99000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
233000 USD
CY2021Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
5501000 USD
CY2020Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
6037000 USD
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
42000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
38000 USD
CY2021Q1 us-gaap Liabilities
Liabilities
15529000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
16163000 USD
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
141429000 shares
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
141429000 shares
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12655000 shares
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12655000 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8349000 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8349000 shares
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
13000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
8000 USD
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
244117000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
204376000 USD
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-382000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-847000 USD
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-202773000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1910000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1468000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-199103000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
40975000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
4434000 USD
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
56504000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20597000 USD
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
675000 USD
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
831000 USD
CY2021Q1 us-gaap Gross Profit
GrossProfit
1235000 USD
CY2020Q1 us-gaap Gross Profit
GrossProfit
637000 USD
CY2021Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1793000 USD
CY2020Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2520000 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
603000 USD
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
711000 USD
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1978000 USD
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2187000 USD
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
4374000 USD
CY2020Q1 us-gaap Interest Expense
InterestExpense
52000 USD
CY2021Q1 ekso Gain Loss On Warrant Liability
GainLossOnWarrantLiability
11000 USD
CY2020Q1 ekso Gain Loss On Warrant Liability
GainLossOnWarrantLiability
2519000 USD
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
5418000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3139000 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4781000 USD
CY2021Q1 us-gaap Interest Expense
InterestExpense
26000 USD
CY2021Q1 ekso Other Income Expense
OtherIncomeExpense
-516000 USD
CY2020Q1 ekso Other Income Expense
OtherIncomeExpense
-220000 USD
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-531000 USD
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2247000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3670000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2534000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
465000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
173000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3205000 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2361000 USD
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10752000 shares
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5803000 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
4434000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3670000 USD
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
35360000 USD
CY2021Q1 ekso Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
3878000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
152000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
356000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
465000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
40975000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
6797000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2534000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
155000 USD
CY2021Q1 ekso Common Stock Contribution
CommonStockContribution
52000 USD
CY2020Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
50000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
587000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
173000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
5228000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3670000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2534000 USD
CY2021Q1 us-gaap Depreciation
Depreciation
126000 USD
CY2020Q1 us-gaap Depreciation
Depreciation
164000 USD
CY2021Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
31000 USD
CY2020Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 USD
CY2021Q1 ekso Gain Loss On Warrant Liability
GainLossOnWarrantLiability
11000 USD
CY2020Q1 ekso Gain Loss On Warrant Liability
GainLossOnWarrantLiability
2519000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
356000 USD
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
587000 USD
CY2021Q1 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
1000 USD
CY2020Q1 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
13000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2000000 USD
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
32000 USD
CY2020Q1 ekso Common Stock Contribution
CommonStockContribution
77000 USD
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-503000 USD
CY2020Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-219000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-917000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2550000 USD
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
228000 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
78000 USD
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
68000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
151000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
96000 USD
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
15000 USD
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
37000 USD
CY2021Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-165000 USD
CY2020Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-312000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2000000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1722000 USD
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
37295000 USD
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2021Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
CY2020Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
589000 USD
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1417000 USD
CY2020Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
38712000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-589000 USD
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-35000 USD
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-45000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
36677000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2356000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12862000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10872000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49539000 USD
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49539000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8516000 USD
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
23000 USD
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
32000 USD
CY2021Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2020Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
3000 USD
CY2021Q1 ekso Fair Value Of Warrants Issued Upon Equity Financing
FairValueOfWarrantsIssuedUponEquityFinancing
1936000 USD
CY2020Q1 ekso Fair Value Of Warrants Issued Upon Equity Financing
FairValueOfWarrantsIssuedUponEquityFinancing
0 USD
CY2021Q1 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
2461000 USD
CY2020Q1 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
0 USD
CY2021Q1 ekso Transfer Of Property And Equipment From Inventory
TransferOfPropertyAndEquipmentFromInventory
53000 USD
CY2020Q1 ekso Transfer Of Property And Equipment From Inventory
TransferOfPropertyAndEquipmentFromInventory
38000 USD
CY2021Q1 ekso Shares Issued Capital Contribution
SharesIssuedCapitalContribution
152000 USD
CY2020Q1 ekso Shares Issued Capital Contribution
SharesIssuedCapitalContribution
155000 USD
CY2021Q1 us-gaap Stock Issued1
StockIssued1
0 USD
CY2020Q1 us-gaap Stock Issued1
StockIssued1
50000 USD
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-202773000 USD
CY2021Q1 ekso Debt Covenant Covenant Compliance Unrestricted Cash
DebtCovenantCovenantComplianceUnrestrictedCash
2000000 USD
CY2021Q1 ekso Unrestricted Cash
UnrestrictedCash
47539000 USD
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to, revenue recognition, deferred revenue and the deferral of the associated costs, the valuation of warrants and employee stock options, future warranty costs, accounting for leases, useful lives assigned to long-lived assets, valuation of inventory, realizability of deferred tax assets, and contingencies. Actual results could differ from those estimates.</span></div>
CY2021Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains cash accounts in excess of federally insured limits. However, the Company believes it is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. The Company extends credit to customers in the normal course of business and performs ongoing credit evaluations of its customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are derived from the sale of products shipped and services performed for customers primarily located in the U.S., Europe, Asia, and Australia. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and provides an allowance for potential credit losses. The Company has not experienced material losses related to accounts receivable as of March 31, 2021 and December 31, 2020. Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, the Company has not experienced significant gains or losses upon settling contracts denominated in a foreign currency.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2021, the Company had one customer with an accounts receivable balance totaling 10% or more of the Company’s total accounts receivable (16%), as compared with two customers at December 31, 2020 (13% and 10%).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, the Company had two customers with sales of 10% or more of the Company’s total revenue (14% and 11%), as compared with one customer in the three months ended March 31, 2020 (16%).</span></div>
CY2021Q1 ekso Number Of Customers
NumberOfCustomers
1 customer
CY2020 ekso Number Of Customers
NumberOfCustomers
2 customer
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
465000 USD
CY2021Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
1530000 USD
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1724000 USD
CY2021Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
279000 USD
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
18000 USD
CY2021Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
345000 USD
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
236000 USD
CY2021Q1 us-gaap Inventory Net
InventoryNet
2154000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
1978000 USD
CY2021Q1 ekso Deferred Extended Maintenance And Support
DeferredExtendedMaintenanceAndSupport
2757000 USD
CY2020Q4 ekso Deferred Extended Maintenance And Support
DeferredExtendedMaintenanceAndSupport
2902000 USD
CY2021Q1 ekso Deferred Royalties
DeferredRoyalties
280000 USD
CY2020Q4 ekso Deferred Royalties
DeferredRoyalties
282000 USD
CY2021Q1 us-gaap Deferred Revenue Leases Net
DeferredRevenueLeasesNet
100000 USD
CY2020Q4 us-gaap Deferred Revenue Leases Net
DeferredRevenueLeasesNet
118000 USD
CY2021Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3137000 USD
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3302000 USD
CY2021Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1493000 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1496000 USD
CY2021Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1644000 USD
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1806000 USD
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3302000 USD
CY2021Q1 ekso Contract With Customer Liability Deferral Of Revenue
ContractWithCustomerLiabilityDeferralOfRevenue
289000 USD
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2276000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3224000 USD
CY2021Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
454000 USD
CY2021Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3137000 USD
CY2021Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3137000 USD
CY2021Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
1193000 USD
CY2021Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
964000 USD
CY2021Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
980000 USD
CY2021Q1 ekso Contractwith Customer Liability Non Cancellable Backlog
ContractwithCustomerLiabilityNonCancellableBacklog
890000 USD
CY2021Q1 us-gaap Lessor Operating Lease Term Of Contract
LessorOperatingLeaseTermOfContract
P12M
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1910000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1468000 USD
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1267000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1194000 USD
CY2021Q1 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
153000 USD
CY2020Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
188000 USD
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
55000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
47000 USD
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1475000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1429000 USD
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49539000 USD
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0 USD
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
2000000 USD
CY2021Q1 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
10000 USD
CY2021Q1 us-gaap Long Term Debt
LongTermDebt
1990000 USD
CY2021Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 USD
CY2021Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1990000 USD
CY2021Q1 us-gaap Long Term Debt
LongTermDebt
1990000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
447000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
235000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
682000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
36000 USD
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
646000 USD
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
547000 USD
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
99000 USD
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
646000 USD
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y2M8D
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.105
CY2021Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
132000 USD
CY2020Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
138000 USD
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
141429000 shares
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12655000 shares
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12655000 shares
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1325000 shares
CY2021Q1 ekso Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
0 shares
CY2021Q1 ekso Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
358000 shares
CY2021Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1240000 shares
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1417000 USD
CY2021Q1 ekso Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
358000 shares
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
356000 USD
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
587000 USD
CY2020 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2021Q1 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
50000 USD
CY2021Q1 us-gaap Contractual Obligation
ContractualObligation
919000 USD
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3670000 USD
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2534000 USD
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10752000 shares
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5803000 shares
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2087000 shares
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1847000 shares
CY2021Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1910000 USD
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
675000 USD
CY2021Q1 us-gaap Gross Profit
GrossProfit
1235000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1468000 USD
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
831000 USD
CY2020Q1 us-gaap Gross Profit
GrossProfit
637000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1910000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1468000 USD

Files In Submission

Name View Source Status
0001549084-21-000025-index-headers.html Edgar Link pending
0001549084-21-000025-index.html Edgar Link pending
0001549084-21-000025.txt Edgar Link pending
0001549084-21-000025-xbrl.zip Edgar Link pending
ekso-20210331.htm Edgar Link pending
ekso-20210331.xsd Edgar Link pending
ekso-20210331_cal.xml Edgar Link unprocessable
ekso-20210331_def.xml Edgar Link unprocessable
ekso-20210331_htm.xml Edgar Link completed
ekso-20210331_lab.xml Edgar Link unprocessable
ekso-20210331_pre.xml Edgar Link unprocessable
ekso-3312021xex311.htm Edgar Link pending
ekso-3312021xex312.htm Edgar Link pending
ekso-3312021xex321.htm Edgar Link pending
ekso-3312021xex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending